Analyzing the cell proliferation marker Ki67 allows for the assessment of tumor growth and invasiveness, which is crucial for predicting the aggressiveness of SRMs, risk stratification, and clinical decision-making (4, 5). This evidence concerns the gene MKI67 and neoplasm.